Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6% Market Closed
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Frontage Holdings Corp
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Other Long-Term Assets
$15.3m
CAGR 3-Years
38%
CAGR 5-Years
99%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Other Long-Term Assets
$4.2B
CAGR 3-Years
12%
CAGR 5-Years
28%
CAGR 10-Years
18%
Danaher Corp
NYSE:DHR
Other Long-Term Assets
$2.5B
CAGR 3-Years
0%
CAGR 5-Years
26%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Other Long-Term Assets
$396.2m
CAGR 3-Years
17%
CAGR 5-Years
27%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Other Long-Term Assets
$733m
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
-6%
IQVIA Holdings Inc
NYSE:IQV
Other Long-Term Assets
$631m
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
15%
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Other Long-Term Assets?
Other Long-Term Assets
15.3m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Other Long-Term Assets amounts to 15.3m USD.

What is Frontage Holdings Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
99%

Over the last year, the Other Long-Term Assets growth was 114%. The average annual Other Long-Term Assets growth rates for Frontage Holdings Corp have been 38% over the past three years , 99% over the past five years .

Back to Top